Chronic kidney disease (CKD) is a main public health challenge (
1), especially in developing countries (
2), which its incidence and prevalence are on the rise (
3). Although patients undergoing hemodialysis, as a maintenance invasive treatment, can live longer (
4), they experience diverse complications that noticeably disturb their quality of life (
5). Patients undergoing hemodialysis have an extremely high risk of developing cardiovascular diseases in comparison with general population (
6); as a result, cardiovascular diseases with vascular calcifications are the most important cause of morbidity and mortality among these patients (
7). Although risk factors, such as hypertension and lipid metabolic disorders (hypercholesterolemia) are more prevalent in the patients with CKD, these factors cannot explain the higher mortality of cardiovascular disease in patients undergoing hemodialysis (
8).
In recent years, it has been found that cardiovascular events and mortality are significantly related to hyperuricemia in the general population and in patients with CKD (
9,
10). Hyperuricemia, represented by increased level of serum uric acid (SUA), is one of the most prevalent disorders in CKD patients and occurs usually during the early stages of the disease (
1). It is accompanied with rapid loss in residual renal function (
11).
Moreover, according to the literature, there was a significant association between cardiovascular mortality and systematic inflammation (
12). Systemic inflammation is a common disorder in patients with CKD, which results from an increase in the production of oxidative stress-free radicals and a reduction in the capacity of antioxidants (
13). It exacerbates with the deterioration of kidney function and hemodialysis inception (
14). In recent years, clinical studies have shown that the precipitation of urate crystals in joints of hyperuricemic patients could lead to the release of inflammatory cytokines (
15) and a systemic inflammation (
16). In other words, inflammation could be involved with elevated serum uric acid; however, this subject has been little investigated in patients undergoing hemodialysis (
17).
C-reactive protein (CRP) that is synthesized during the inflammation by liver is a reliable marker for showing the inflammatory state and response (
18). Although the role of ferritin is storing intracellular iron (
19), it may have other effects. Limited evidence shows that high levels of serum ferritin could aggravate oxidative stress in patients undergoing hemodialysis (
20); however, we have not found any study reporting serum levels of inflammation markers in hemodialysis patients with high, normal or low serum levels of ferritin.